Johnson & Johnson antiviral pill for dengue shows early efficacy

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we see data from ESMO showing that Roche’s alectinib works well in some early stage lung cancers, see our first preventative dengue pill, and more.

The need-to-know this morning
• The “Roi” in Roivant Sciences stands for “return on investment” and with a blockbuster deal announced Monday, the biotech certainly delivered. Last December, it essentially acquired an experimental drug for inflammatory bowel diseases from Pfizer for $45 million and a commitment to invest in the drug’s development. Less than a year later, Roivant is selling the drug, called RVT-3101, to Roche for at least $7.1 billion.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In